SB-218078

  • CAT Number: I009313
  • CAS Number: 135897-06-2
  • Molecular Formula: C24H15N3O3
  • Molecular Weight: 393.402
  • Purity: ≥95%
Inquiry Now

SB-218078 (Cat.No:I009313) is a potent and selective indolocarbazole chk1 inhibitor.

Catalog Number I009313
CAS Number 135897-06-2
Molecular Formula

C24H15N3O3

Purity 95%
Target Chk
Solubility Soluble in DMSO, not in water
Storage Store at -20°C
InChI InChI=1S/C24H15N3O3/c28-23-19-17-11-5-1-3-7-13(11)26-15-9-10-16(30-15)27-14-8-4-2-6-12(14)18(22(27)21(17)26)20(19)24(29)25-23/h1-8,15-16H,9-10H2,(H,25,28,29)
InChIKey OTPNDVKVEAIXTI-UHFFFAOYSA-N
SMILES C1CC2N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N(C1O2)C7=C53)C(=O)NC6=O
Reference

</br>1:Jennings-Gee J, Pardee TS, Gmeiner WH. Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Exp Hematol. 2013 Feb;41(2):180-188.e4. doi: 10.1016/j.exphem.2012.10.007. Epub 2012 Oct 17. PubMed PMID: 23085462; PubMed Central PMCID: PMC3660094.</br>2:Park JH, Kim WS, Kim JY, Park MH, Nam JH, Yun CW, Kwon YG, Jo I. Chk1 and Hsp90 cooperatively regulate phosphorylation of endothelial nitric oxide synthase at serine 1179. Free Radic Biol Med. 2011 Dec 15;51(12):2217-26. doi: 10.1016/j.freeradbiomed.2011.09.021. Epub 2011 Sep 25. PubMed PMID: 22001744.

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!